Biohealth Innovation
Mike Baader, the head of Venable’s Baltimore office, will be joining the law firm’s longtime client, Greenspring Associates, as a partner and general counsel, sources said.
The sources said Baader will stay on with the firm for several months to assist in the transition. Courtney Capute has been named to succeed Baader as head of the law firm’s Baltimore practice.
The National Institutes of Health contracting arm has launched a $20 billion governmentwide acquisition program, Nextgov reports based on solicitation documents.
RCT Ventures has just announced a new opportunity for early-stage medical device companies: the 2014 MedTech Innovator competition. Companies and university-stage teams are encouraged to apply. Ten semi-finalists will be selected by a panel of medical device venture capitalists that will receive free registration to the Wilson Sonsini Medical Device conference. There, a live audience will select the winner, who will receive the $100k grand prize.
RCT Ventures’ last contest, Medtech Idol, had a fascinating array of gadgety competition with Aventamed‘s impressive ear-tube placement device coming out on top. When asked about the competition, Paul Grand, Managing Director for RCT Ventures said, “In today’s lean start-up model, the $100k prize should be enough to allow the winner to bridge the funding gap and achieve a milestone that can help them secure a larger funding round or critical industry partnership.”
Join members from NHLBI's SMARTT team on May 28, 2014 (1:00-2:30 pm EST) for a free webinar to hear how three investigators utilized SMARTT services to advance the development of their lead candidates.
Webinar agenda
Representatives from NHLBI staff and from SMARTT’s regulatory, manufacturing, and pharmacology/toxicology facilities will be available to answer questions.
“Hi, my name is Krzysztof Sitko, cofounder of Aegle, and I’m going to tell you today about how we failed throughout all of DreamIt Health, and why you might consider investing in us anyhow.”
A month ago, that wasn’t how I pictured my presentation at our startup accelerator’s Demo Day. I was working tirelessly alongside my cofounders to put together a business. Yet there I was in front of a room of 200 to announce that we didn’t have a market for the product we had been working on.
THIS MOBILE HEALTH TOOL HELPS PEOPLE TO BE ABLE TO CONFRONT THEIR ANXIETIES AND THEIR FEARS.
A new self-help tool has now been developed by a team of psychologists, physicists, and developers, which uses augmented reality over a mobile health platform, with the goal of helping users to be able to treat their phobias and overcome their anxieties.
Maryland lawmakers have penned a letter to Pfizer asking the New York-based pharmaceutical giant to ensure that it will not shed jobs at Gaithersburg-based MedImmune should it succeed in acquiring parent company AstraZeneca.
Pfizer has offered as much as $106 billion to acquire United Kingdom-based AstraZeneca in a deal that could rank among the largest ever for the pharmaceutical industry. So far, the companies have not agreed on a purchase price.
San Diego-based biopharmaceuticals developer Lumena Pharmaceuticals has been acquired by UK-based Shire plc, in a deal worth $260M plus earn out, the companies said this morning. Shire said the buy would help add to its rare diseases portfolio. Lumena Pharmaceuticals had filed for an IPO in April; the company was venture backed by Alta Partners, New Enterprise Associates, RiverVest, A.M. Pappas Life Sciences Ventures, and Adage Capital Partners.
The recently published "Johns Hopkins Guide to Digital Media", weighing in at over five hundred pages, claims to be the first "systematic and comprehensive" reference work on digital media. However, the reader need only scan the table of contents with entries ranging from the expected, such as "Blogs," to the obscure such as "Searle's Chinese Rooms," to appreciate that it is neither systematic nor comprehensive. And, this is not necessarily a bad thing. For, The Guide does indeed accomplish what it sets out to do: provide readers with " a GPS and a map of the territory of digital media, so that they will be able to design their own journey through this vast field of discovery."
D.C. startup incubator and co-working campus 1776 filed paperwork with the SEC to create a $25 million seed investment fund according to a report in the Washington Business Journal. The filing, issued in the name of "1776 Seed Investors, LP," would be part of a longer term plan by 1776 to start funding startups while it continues to incubate them at its D.C. headquarters.
Drug targets are like fashion items. When a trendsetter proves one is worth spending money on, a lot of followers pile in. That’s no knock on drug developers, necessarily: When a new target shows some promise, it’s good to have lots of researchers with different ideas and approaches trying to find a drug to hit it. In the last few years, many of those researchers from the academic and industry camps who traditionally wouldn’t work together are joining forces.
Enter drug giant GlaxoSmithKline (NYSE: GSK), which has tried various schemes to make its research groups more biotech-like, including the spin-out of an immunology team into a separate biotech company. That company, Tempero Pharmaceuticals of Cambridge, MA, has teamed up with two academic labs to go after one of the most intriguing targets in immune disease, the IL-17 pathway, and a paper they published recently has caught the eyes of their peers.
Ready to put an end to a devastating disease, Maryland-based biotechnology company Sanaria launched a crowdfunding campaign on Indiegogo to eliminate the threat of malaria. The company is aiming to raise $250k to develop of SporoBot, a robot that will dissect mosquito salivary glands and to accelerate vaccine development.
Malaria is a vector borne disease that is transmitted by the bite of an infected mosquito. During the bite, it regurgitates parasitic protozoa Plasmodium falciparum. This is then embedded in the host’s liver until it matures and releases its progeny. It then destroys the host’s red cells and ultimately kills the host.
Digital health is a popular business these days, but it’s also a tricky one.
In theory, remote monitoring and engagement products have the potential to drive long-term cost savings, but robust data is lacking and consumer adoption so far has been relatively low.
During the Spring 2014 Maryland legislative session, the Biotechnology Investment Incentive Tax Credits were increased by $2M to $12M. The electronic queue for these credits will take place on July 1, 2014. To participate in this queue, companies must register by submitting their complete application (form A1/A2/A3 and form B) to the Maryland Department of Business and Economic Development (DBED) Tax Incentives Group between June 2nd and June 27th.
Companies seeking to confirm their QMBC (Qualified Maryland Biotechnology Company) status prior to June 2nd may do so by submitting their company's information (form B) to DBED between May 19th and May 30th.
Join us at another BioBuzz event with Sponsor The UMD Biotechnology Research and Education Program (BREP) on May 21st from 5:00 - 7:30 p.m. at American Tap Room in Rockville, MD. .This location is a short walk from the Metro in the Rockville Town Center. We're capping the registration at 120 people, so make sure you sign up today!
The Government Contracting Institute, sponsored by TargetGov and bwtech@UMBC, introduces a new class covering the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. The class, called “How the SBIR/STTR Program Can Help Grow Your Business” will be held at bwtech@UMBC’s South Campus on May 27, 2014. Representatives from the Department of Homeland Security (DHS) and the National Institutes of Health (NIH) will be an integral part of the class instruction.
The SBIR/STTR programs promote small business innovation and profitability while simultaneously meeting the government’s research and development needs. Every year, small businesses receive millions of dollars in SBIR/STTR funds for research, development and commercialization purposes. This course will provide attendees with an overview of the SBIR/STTR programs; funding sources and eligibility requirements; best practices in SBIR/STTR proposals writing, involvement, and commercialization; and a discussion of how to protect your company’s legal interests in either program.
Genome pioneer J. Craig Venter is teaming up with a unit of United Therapeutics to develop pig lungs that have been genetically altered to be compatible with humans, a feat that, if successful, could address the urgent need for transplant organs for people with end-stage lung disease.
Venter's privately held company Synthetic Genomics said it has entered a multiyear deal with United Therapeutics' Lung Biotechnology to develop the so-called humanised pig organs.
The Maryland Science Center's newly expanded and re-imagined space, SciLab , is now open, providing a unique, popular and hands-on laboratory science simulation for visitors. The 2,000-square-foot expansion was partially funded by a $100,000 contribution from BD Diagnostics, a segment of BD (Becton, Dickinson and Company) BDX +1.01% , a leading global medical technology company. SciLab's expansion includes a classroom space, new investigation stations and additional laboratory gear that enhance educational opportunities for visitors and local school groups.
Visitors to SciLab will don lab coats, wear safety glasses and experiment with dozens of lab tools at large investigation stations to explore scientific wonders including chemical composition analysis, DNA extraction, optical illusions and the inner workings of the human body. "SciLab Scientists" will use test tubes, pipettes, beakers and microscopes while measuring, mixing, stirring and observing their way to testing a hypothesis.
Nearly 30 business incubators throughout Maryland are fostering the next generation of entrepreneurs, breaking down barriers to entry and introducing new talent to investors.
For the past 14 years, organizers of the Maryland Incubator Company of the Year Awards have honored the most promising startups emerging from the State’s incubators. From among 22 finalists, this year’s category winners will be announced at the American Visionary Art Museum in Baltimore on June 10, the competition announced Wednesday.
The Intellectual Property & Science business of Thomson Reuters , the world's leading provider of intelligent information for businesses and professionals, honored Amplimmune, Inc. and Medimmune for their work in pharmaceutical Mergers and Acquisitions (M&A), and Isis Pharmaceuticals and Biogen Idec for biopharmaceutical licensing with the Allicense 2014 Breakthrough Award for Deal of the Year .
The winners were announced Tuesday, April 29, after a public vote at 2014 Allicense , a prominent event connecting business development, licensing, and merger and acquisition (M&A) professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical development. The annual award honors the top global deals in two categories: M&A and Biopharmaceutical Licensing. Five contenders in each category were nominated by Thomson Reuters deals analysts after a thorough analysis of information in Thomson Reuters Recap —the premier analysis tool for biopharmaceutical business deal making—and other criteria that examined hundreds of deals negotiated throughout 2013.
Top Story: QMBC Determinations for the Maryland Biotech Investment — Incentive Tax Credits (BIITC) Begin May 19th; Line-up July 1st
The electronic line-up for the next round of Maryland Biotechnology Investment Incentive Tax Credits (BIITC) will take place July 1, 2014. To participate in this queue, companies must register by submitting their completed application (Form A and Form B) to the Maryland Department of Business and Economic Development (DBED) Tax Incentives Group between June 2nd and June 27th.
Companies seeking to confirm their QMBC (Qualified Maryland Biotechnology Company) status prior to June 2nd may do so by submitting their company's information (Form B) to DBED's Tax Incentives Group between May 19th and May 30th.
Johns Hopkins University and the University of Maryland, College Park are among the nation’s best engineering schools.
Johns Hopkins ranks 17th and the University of Maryland 24th, according to Business Insider.
The report is the third in an annual series briefing Congress on the results of legislative language in the America Competes Reauthorization Act of 2010 that encourages the use of prize competitions by federal agencies to spur innovation.
In the private sector, such competitions have occasionally become major spectacles, such as the 1927 Orteig Prize that led to Charles Lindbergh’s trans-Atlantic flight and the $10-million prize a decade ago for the successful launch of a commercial spacecraft. But in the arena of federally sponsored science, and especially as it concerns the basic research done at universities, the uses appear more limited, such as tackling logistical roadblocks or developing web applications.
When Ron Daniels took the stage in a fourth floor auditorium inside the Johns Hopkins University Medical Center in East Baltimore, he was staring down a veritable Who’s Who of Baltimore city’s tech community: startup founders, the presidents and operators of incubators, people at the helm of deep-pocketed foundations and tech company investors.
It was April 30, Demo Day for DreamIt Health Baltimore, when nine health IT startups would graduate from a four-month accelerator program backed, in part, by the Johns Hopkins University. And Daniels, president of Johns Hopkins, had one message for the startups’ founders anxiously awaiting their turn to present their companies to the crowd of at least 100.
Foluke Tuakli hopped on a bicycle and weaved around her classroom at the University of Maryland, College Park, acting out the problems that cyclists encounter on the road. "I'm turning, I'm turning," she shrieked as the bike wobbled.
The demonstration was part of a student pitch for a bicycle GPS app in a freshman entrepreneurship class in the honors college. Other student groups had their own pitches: a new type of sustainable drinking fountain where water is squirted directly into the mouth, a Third World slum development project, and a day care center that emphasizes healthful eating habits.
The University of Maryland and the National Institute for Standards and Technology (NIST) will host the first national symposium to discuss biosimilar therapeutics on June 13, 2014, at the Institute for Bioscience and Biotechnology Research in Rockville, Md., university officials announce today.
The event, " Emerging Strategies for the Production and Characterization of Biosimilars ," kicks off the first annual UMD/NIST Biomanufacturing Technology Summit, which pulls together company, government and academic thought leaders from around the world each year to discuss strategies, trends and issues in biotechnology products and manufacturing.
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notices:
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Two University of Maryland graduates have designed The Micro, a consumer-friendly, sub-$300 3D printer, and are quickly staging one of the most successful Kickstarter campaigns of all-time to produce it, hauling in $3.3 million with more than 10,000 backers.
The Micro raced past its $50,000 goal in just 11 minutes and hit the $1 million mark in 25 hours, faster than the Pebble watch, which took 28 hours.
The number of people age 65 and older in the United States is expected to almost double by 2050, a shift that is expected to drastically alter the nation's racial makeup and pressure its economy, two government reports released on Tuesday said.
Those older U.S. residents are expected grow from 43 million in 2012 to nearly 84 million over the next four decades as the baby boomer generation ages, the Census Bureau said in its latest estimate.
The National Institutes of Health (NIH) has awarded a contract to researchers at The Johns Hopkins University to launch a new center devoted to developing innovative ways to identify and track influenza viruses worldwide.
One top goal is to rapidly identify new influenza virus strains that may emerge as the next seasonal influenza or global pandemic that could threaten public health.
Michael Spinosa overflows with enthusiasm about the team that helped his Columbia company figure out new strategies for growth — at no charge.
That might not sound like economic development, if your conception of it is multimillion-dollar incentives to tempt big employers to move in. The assistance Spinosa got is a different approach with the same goal: more jobs.
Novavax Inc. believes it has created a vaccine against the Middle East Respiratory Virus, or MERS, which has been causing pandemic concerns.
The Gaithersburg biotech, working with University of Maryland School of Medicine researchers, said their vaccine candidate blocked MERS infections in laboratory studies. It is based on a platform for a vaccine candidate that is said to protect against Severe Acute Respiratory Syndrome, or SARS; both MERS and SARS are coronaviruses.
Emocha, one of nine graduates of the first class of startups from the DreamIt Health Baltimore accelerator, announced at Demo Day on April 30 that it’s opening an investment round this summer.
The mobile health platform is already being used in three separate pilot programs to allow physicians and clinicians based at health organizations to monitor patients’ symptoms, recovery and rehabilitation from a variety of diseases via smartphone.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its artus C. difficile QS-RGQ MDx Kit has been cleared by the U.S. Food and Drug Administration to qualitatively detect Clostridium difficile, a widespread healthcare-associated infection (HAI). In addition, the FDA has granted 510(k) regulatory clearance for the QIAsymphony RGQ MDx system, QIAGEN’s flagship automation platform that is transforming laboratory workflows and driving dissemination of molecular diagnostics. The U.S. milestone for QIAGEN’s global rollout of its sample-to-result automation platform, together with the FDA clearance of the first in a portfolio of tests for HAI infections, supports the expected growth in QIAsymphony placements globally to more than 1,250 by year-end 2014 and 1,500 by year-end 2015.
“Our QIAsymphony RGQ platform is revolutionizing laboratory workflows with flexible, efficient automation from sample to result – and the U.S. clearance affirms that we are well on track with our targets for this important growth driver,” said Peer M. Schatz, Chief Executive Officer. “QIAGEN is now positioned to rapidly expand the menu of standardized, regulator-approved diagnostic kits running on QIAsymphony. Our FDA cleared artus C. difficile QS-RGQ MDx Kit provides reliable detection of both the Toxin A and Toxin B of the infection. artus C. difficile QS-RGQ MDx Kit is the first test of our planned HAI portfolio in the United States. As we continue to deliver on a deep pipeline for infectious diseases and personalized healthcare diagnostics, the growing menu adds value for customers and patients by allowing consolidation of more tests on this platform.”
The rising prevalence of smartphones and mobile phones has made their use as a way to help people manage their health more viable. So much so that the National Institutes of Health has started an mhealth grants program and is looking for submissions.
It plans to offer awards of up to $500,000. Self management of chronic conditions and improving patient-provider communications are among the sought-after areas. It begins accepting applications today through May.